Researchers discover adhesive strategy of H. pylori
17 August 2015 | By Victoria White
Researchers from have identified the molecular mechanism that an adhesion protein of H. pylori uses to attach to stomach ulcers...
List view / Grid view
News
Epstein-Barr virus vaccine induces potent neutralising antibodies
17 August 2015 | By Victoria White
Researchers have developed an experimental, nanoparticle-based vaccine against Epstein-Barr virus that can induce potent neutralising antibodies in animals...
Cells regenerate liver without cancer risk
17 August 2015 | By Victoria White
Researchers supported by the NIH have discovered a type of cell, known as hybrid hepatocytes, essential to regeneration of the liver...
AmpliPhi Biosciences announce financial results Q2 2015
14 August 2015 | By Katie Sadler, Digital Content Producer, Drug Target Review
Biotechnology company, AmpliPhi Biosciences Corporation, released financial results for the second quarter 2015 and operational highlights. AmpliPhi, one of the leaders in the development of bacteriophage-based antibacterial therapies to treat antibiotic-resistant infections, has reported strong overall performance in overall liquidity and balance sheet strength thanks to a $13 million investment…
Research suggests ion channel blocking drugs could be used in cancer therapy
12 August 2015 | By Author: Katie Sadler, Digital Content Producer, Drug Target Review
Research carried out by University of California San Francisco (UCSF) has revealed ion channel blocking drugs could play a part in cancer therapy. The common class of channel blocking drugs, which are used to treat cardiac, neurological, and psychiatric disorders, could prove to be beneficial in cancer treatment according to…
Research identifies trigger responsible for regenerating hair and skin after trauma
11 August 2015 | By Katie Sadler, Digital Content Producer, Drug Target Review
Johns Hopkins researchers have identified a novel cell signalling pathway in mice through which mammals can regenerate hair and skin while healing from wounds. The discovery, summarised in an article published on 6th August in the journal Cell Stem Cell, could, they say, eventually help spur the growth of new…
Merus prevails in inequitable conduct case against Regeneron
10 August 2015 | By Charlotte Batchelor
Court ruling further strengthens Merus’ freedom to operate in using transgenic mice for therapeutic human antibodies...
Round 8 of Biomedical Catalyst awards announced
10 August 2015 | By Charlotte Batchelor, Drug Target Review
Twelve new treatments, diagnostics and medical technologies will receive funding from the eighth round of the successful Biomedical Catalyst (BMC)...
Key paper on proteomics in the field of allergy published in the World Allergy Journal
10 August 2015 | By Charlotte Batchelor, Drug Target Review
Allergy Therapeutics has announced the publication of a key paper and featured article in the World Allergy Journal about proteomics in the field of allergy...
Scientists mimic realistic tumour conditions
6 August 2015 | By Victoria White
Researchers placed cancer cells in a three-dimensional scaffold and subjected them to the forces that push, pull and continually flow through the body...
Scientists make strides towards therapeutics for relapse prevention
6 August 2015 | By Victoria White
Scientists have made a discovery that brings them closer to a relapse prevention therapy based on selectively erasing dangerous drug-associated memories...
Scientists discover why moles stop growing
6 August 2015 | By Victoria White
Researchers from the University of Pennsylvania have identified a major genetic factor that keeps moles in their usual non-cancerous, no-growth state...
MedImmune and Mirati in lung cancer therapy collaboration
6 August 2015 | By Victoria White
MedImmune has entered into an exclusive clinical trial collaboration with Mirati Therapeutics to evaluate durvalumab in combination with mocetinostat...
AstraZeneca and Heptares to develop novel immuno-oncology treatments
6 August 2015 | By Victoria White
AstraZeneca and Heptares Therapeutics have entered into a licensing agreement to develop A2A receptor-blocking compounds as cancer immunotherapies...
ADXS-PSA awarded grants from PCF and Movember Foundation
5 August 2015 | By Victoria White
Two research projects involving ADXS-PSA, which is being developed for prostate cancer, have been selected for 2015 Movember Foundation-PCF Challenge Awards...